返回
Shenzhen Hepalink Pharmaceutical Group Co Ltd (SHEZF) 收益
SHEZF 股價走勢圖
SHEZF 收益
Shenzhen Hepalink Pharmaceutical Group Co Ltd
$0.46
0%
$0
截至今日：Mar 24, 14:15:12 GMT-4
Earnings FAQ
SHEZF 最近的每股盈餘與預期相比如何？
Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF 上一季度的收入表現如何？
Shenzhen Hepalink Pharmaceutical Group Co Ltd 的收入預期是多少？
Shenzhen Hepalink Pharmaceutical Group Co Ltd 的盈利品質評分是多少？
Shenzhen Hepalink Pharmaceutical Group Co Ltd 何時發布財報？
Shenzhen Hepalink Pharmaceutical Group Co Ltd 的預期收益是多少？
Shenzhen Hepalink Pharmaceutical Group Co Ltd 是否超出收益預期？
關鍵數據
前收市價
$0.4696
開盤價
$0.7206
當日範圍
$0.4696 - $0.7206
52週區間
$0.4696 - $0.7206
交易量
25
平均成交量
0
股息收益率
--
每股盈餘 (TTM)
-0.02
市值
$689.0M
什麼是 SHENZHEN HEPALINK PHARMACEUTICA？
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 1,926 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the heparin industry chain, contract development and manufacturing organization (CDMO) of biological macromolecules, and the investment, development, and commercialization of innovative drugs. The firm operates four segments. The Pharmaceutical Formulations segment manufactures and sells enoxaparin sodium injection and others. The Active Pharmaceutical Ingredients (APIs) segment manufactures and sells standard heparin APIs, enoxaparin APIs and others. The CDMO segment provides process development services for pharmaceutical intermediates and APIs, including process research, optimization, analytical testing, and formulation research. The Other segment engages in other product businesses, such as pancreatic enzymes and casings. The firm conducts its business in the domestic and overseas markets.